title: [Tumor lysis syndrome].
abstract: Tumor lysis syndrome (TLS) is a serious adverse event observed in patients treated for hematologic malignancies and solid tumors, particularly those with a high proliferative rate. An abrupt and massive tumor cell lysis with release their contents into the circulation leads to a rapid development of hyperuricemia, hyperkalemia, hyperphosphatemia, followed by hypocalcemia. If not managed appropriately, these metabolic disturbances may result in acute kidney injury and in life-threatening cardiac complications and even death. This short review summarizes current strategies for diagnosis, risk assessment, prophylaxis, and therapy.
authors.affiliation: Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych, Warszawski Uniwersytet Medyczny, Warszawa.
authors.forename: Mariusz
authors.initials: M
authors.lastname: Mieczkowski
authors.affiliation: Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych, Warszawski Uniwersytet Medyczny, Warszawa.
authors.forename: Joanna
authors.initials: J
authors.lastname: Matuszkiewicz-Rowińska
authors.affiliation: Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych, Warszawski Uniwersytet Medyczny, Warszawa.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Kościelska
mesh_terms: D006801:Humans; D007674:Kidney Diseases / Q000175:diagnosis / Q000628:therapy; D009369:Neoplasms / Q000150:complications* / Q000628:therapy; D015275:Tumor Lysis Syndrome / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*